The global primary biliary cholangitis therapeutics market size was estimated to be USD 2.34 billion in 2023 and is expected to reach USD 4.98 billion by 2034 with a CAGR of 7.12% during the forecast period 2024-2034. Increasing awareness and diagnosis, advancements in research and development, collaborations and partnerships, government initiatives and support, and personalized medicine approaches will drive the market growth. Research points to a possible increase in occurrences of Tourette Syndrome, while the causes of this increase are still being looked at. There is a greater need on the market for efficient treatment options due to the rising number of people with Tourette Syndrome.
Partnerships among pharmaceutical corporations, academic institutions, and healthcare organizations can stimulate the creation of novel therapeutics and improve the treatment environment as a whole. Understanding the molecular and genetic components of Tourette Syndrome better may enable the creation of individualized treatment plans based on the unique characteristics of each patient. For instance, Neurocrine Biosciences submitted a supplementary New Drug Application (sNDA) to the FDA in December 2023, requesting that the label for Ingrezza be amended to cover juvenile tardive dyskinesia associated with Tourette Syndrome.
By product, the antipsychotics segment accounted for the highest revenue-grossing segment in the global Primary Biliary Cholangitis Therapeutics market in 2023 owing to the innovative formulations and expanded treatment options, as well as the proven efficacy of antipsychotics in managing the symptoms associated with Primary Biliary Cholangitis. For instance, in October 2023, Teva Pharmaceutical Industries presented evidence at the CHMP (Committee for Medicinal Products for Human Use) meeting on tetrabenazine's potential for treating tardive dyskinesia in adult Tourette Syndrome patients. Additionally, the non-antipsychotics segment is predicted to grow at the fastest CAGR during the forecast period owing to advancements in targeted therapies, increased research and development efforts, and a growing preference for treatment modalities with fewer side effects.
By distribution channel, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global Primary Biliary Cholangitis Therapeutics market in 2023 owing to the rising patient admissions, increased diagnostic procedures, and the centralized role of hospitals and clinics in providing comprehensive and specialized care for Primary Biliary Cholangitis. For instance, Pfizer entered into a collaborative agreement with Sozdarai Therapeutics in June 2023 to develop and market innovative gene therapy candidates for neurological illnesses, including Tourette Syndrome. Additionally, the online retailers segment is predicted to grow at the fastest CAGR during the forecast period owing to increased digital adoption, rising consumer preference for online purchasing, and the convenience and accessibility offered by online retailers in the distribution of Primary Biliary Cholangitis Therapeutics.
North American region is anticipated for the highest revenue share during the forecast period owing to the robust healthcare infrastructure, a high prevalence of Primary Biliary Cholangitis cases, and a strong emphasis on research and development activities. For instance, Johnson & Johnson announced the start of a new patient support program called "Living with Tourette Syndrome" in September 2023 to give services and information to individuals and families impacted by the illness. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of Primary Biliary Cholangitis, expanding healthcare infrastructure, and a growing focus on healthcare improvements.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Partnerships among pharmaceutical corporations, academic institutions, and healthcare organizations can stimulate the creation of novel therapeutics and improve the treatment environment as a whole. Understanding the molecular and genetic components of Tourette Syndrome better may enable the creation of individualized treatment plans based on the unique characteristics of each patient. For instance, Neurocrine Biosciences submitted a supplementary New Drug Application (sNDA) to the FDA in December 2023, requesting that the label for Ingrezza be amended to cover juvenile tardive dyskinesia associated with Tourette Syndrome.
By product, the antipsychotics segment accounted for the highest revenue-grossing segment in the global Primary Biliary Cholangitis Therapeutics market in 2023 owing to the innovative formulations and expanded treatment options, as well as the proven efficacy of antipsychotics in managing the symptoms associated with Primary Biliary Cholangitis. For instance, in October 2023, Teva Pharmaceutical Industries presented evidence at the CHMP (Committee for Medicinal Products for Human Use) meeting on tetrabenazine's potential for treating tardive dyskinesia in adult Tourette Syndrome patients. Additionally, the non-antipsychotics segment is predicted to grow at the fastest CAGR during the forecast period owing to advancements in targeted therapies, increased research and development efforts, and a growing preference for treatment modalities with fewer side effects.
By distribution channel, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global Primary Biliary Cholangitis Therapeutics market in 2023 owing to the rising patient admissions, increased diagnostic procedures, and the centralized role of hospitals and clinics in providing comprehensive and specialized care for Primary Biliary Cholangitis. For instance, Pfizer entered into a collaborative agreement with Sozdarai Therapeutics in June 2023 to develop and market innovative gene therapy candidates for neurological illnesses, including Tourette Syndrome. Additionally, the online retailers segment is predicted to grow at the fastest CAGR during the forecast period owing to increased digital adoption, rising consumer preference for online purchasing, and the convenience and accessibility offered by online retailers in the distribution of Primary Biliary Cholangitis Therapeutics.
North American region is anticipated for the highest revenue share during the forecast period owing to the robust healthcare infrastructure, a high prevalence of Primary Biliary Cholangitis cases, and a strong emphasis on research and development activities. For instance, Johnson & Johnson announced the start of a new patient support program called "Living with Tourette Syndrome" in September 2023 to give services and information to individuals and families impacted by the illness. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of Primary Biliary Cholangitis, expanding healthcare infrastructure, and a growing focus on healthcare improvements.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Tourette Syndrome Treatment Market Report 2023 - 2034
Tourette Syndrome Treatment Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Antipsychotics
- Non-Antipsychotics
- Stimulants
- Alpha-2 adrenergic agonists
Tourette Syndrome Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospitals and Clinics
- Pharmacies
- Online Retailers
Tourette Syndrome Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Tourette Syndrome Treatment Market: Product Estimates & Trend Analysis
8. Tourette Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Tourette Syndrome Treatment Market
11. Europe Global Tourette Syndrome Treatment Market
12. Asia Pacific Global Tourette Syndrome Treatment Market
13. Latin America Global Tourette Syndrome Treatment Market
14. MEA Global Tourette Syndrome Treatment Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Neurocrine Biosciences Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Johnson & Johnson
- Eli Lilly and Company
- Abide Therapeutics
- Takeda Pharmaceutical Company Limited
- Psyadon Pharmaceuticals.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.34 Billion |
| Forecasted Market Value ( USD | $ 4.98 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
